Robbie Marcus
Stock Analyst at JP Morgan
(3.97)
# 558
Out of 4,876 analysts
161
Total ratings
55.45%
Success rate
8.86%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Downgrades: Neutral | $110 → $76 | $71.14 | +6.83% | 5 | May 30, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $14 → $16 | $10.71 | +49.39% | 5 | May 14, 2025 | |
| CVRX CVRx, Inc. | Downgrades: Underweight | $15 → $7 | $5.82 | +20.27% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Overweight | $128 → $105 | $91.46 | +14.80% | 6 | May 6, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $12 | $12.29 | -2.36% | 6 | May 6, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $235 → $195 | $132.41 | +47.27% | 5 | May 6, 2025 | |
| CNMD CONMED | Maintains: Neutral | $70 → $58 | $52.17 | +11.18% | 7 | May 1, 2025 | |
| RXST RxSight | Downgrades: Underweight | $40 → $17 | $12.67 | +34.18% | 5 | Apr 4, 2025 | |
| MMSI Merit Medical Systems | Initiates: Overweight | $120 | $93.50 | +28.34% | 1 | Mar 28, 2025 | |
| BAX Baxter International | Maintains: Neutral | $38 → $36 | $30.39 | +18.46% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $393.55 | +13.07% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $533.71 | +26.47% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $6.77 | +92.02% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $106.53 | +3.26% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $313.08 | +5.40% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $18.90 | +69.31% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $32.28 | +23.92% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $78 | $78.21 | -0.27% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $86.33 | -1.54% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $74.38 | +21.00% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $31.78 | +57.33% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $5.75 | +39.13% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $256.43 | -2.51% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $9.26 | +72.79% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $7.08 | -1.13% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $12.40 | +37.10% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $134.38 | -12.19% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $154.71 | +0.83% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $86.02 | +22.06% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $101.42 | -60.56% | 2 | May 5, 2020 |
The Cooper Companies
May 30, 2025
Downgrades: Neutral
Price Target: $110 → $76
Current: $71.14
Upside: +6.83%
NeuroPace
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $10.71
Upside: +49.39%
CVRx, Inc.
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $5.82
Upside: +20.27%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Overweight
Price Target: $128 → $105
Current: $91.46
Upside: +14.80%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Underweight
Price Target: $24 → $12
Current: $12.29
Upside: -2.36%
Inspire Medical Systems
May 6, 2025
Maintains: Overweight
Price Target: $235 → $195
Current: $132.41
Upside: +47.27%
CONMED
May 1, 2025
Maintains: Neutral
Price Target: $70 → $58
Current: $52.17
Upside: +11.18%
RxSight
Apr 4, 2025
Downgrades: Underweight
Price Target: $40 → $17
Current: $12.67
Upside: +34.18%
Merit Medical Systems
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $93.50
Upside: +28.34%
Baxter International
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $30.39
Upside: +18.46%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $393.55
Upside: +13.07%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $533.71
Upside: +26.47%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $6.77
Upside: +92.02%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $106.53
Upside: +3.26%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $313.08
Upside: +5.40%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $18.90
Upside: +69.31%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $32.28
Upside: +23.92%
Oct 25, 2024
Maintains: Neutral
Price Target: $72 → $78
Current: $78.21
Upside: -0.27%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $86.33
Upside: -1.54%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $74.38
Upside: +21.00%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $31.78
Upside: +57.33%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $5.75
Upside: +39.13%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $256.43
Upside: -2.51%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $9.26
Upside: +72.79%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $7.08
Upside: -1.13%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $12.40
Upside: +37.10%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $134.38
Upside: -12.19%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $154.71
Upside: +0.83%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $86.02
Upside: +22.06%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $101.42
Upside: -60.56%